Keywords:
Abdomen, Kidney, Oncology, CT, Treatment effects, Neoplasia
Authors:
A. D. Sotomayor1, B. Paño Brufau2, J. M. Gutiérrez1, B. Mellado2, O. Reig2, M. C. Sebastia2; 1Barcelona, Barcelona/ES, 2Barcelona/ES
DOI:
10.1594/ecr2013/C-1596
Methods and Materials
From May 2011 to May 2012,
patients meeting the following inclusion criteria were enrolled in this prospective study:
- Patients with metastatic RCC candidates for therapy with sunitinib.
- Life expectancy ≥ 3 months.
- Signed informed consent.
Sunitinib was administered according to standard schedule,
50mg orally once daily for four weeks,
followed by two weeks off treatment.
Treatment was continued until disease progression or unacceptable toxicity.
A thoraco-abdominal CT in arterial and venous phase and a volumetric study with perfusion-CT (Flash Definition,
Siemens,
Erlangen,
Germany) were performed at baseline,
1 month and 4 months after therapy with sunitinib.
The volumetric perfusion CT protocol involves coverage of 21 cm with helix repetitions every 2 s,
during 45 s,
after administration of 50mL of non-ionic iodinated contrast agent at 4mL/sec rate.
For this preliminary data analysis,
changes in size,
arterial phase density (D) (normalized by dividing the value by the patient’s aortic attenuation),
and blood flow (BF) perfusion parameter between the baseline study and the study performed 1 month after therapy with the first cycle of sunitinib were evaluated.
Increase and decrease of the parameters analyzed were defined as changes higher than 10% and lower than 10%,
respectively.
Stability was defined as absence of increase or decrease.